Introduction {#section5-1758835918820298}
============

*BRAF* (v-raf murine sarcoma viral oncogene homolog B1) mutations are present in 5--10% of patients with metastatic colorectal cancer (mCRC).^[@bibr1-1758835918820298][@bibr2-1758835918820298]--[@bibr3-1758835918820298]^ The mutation resulting in valine to glutamic acid substitution in codon 600 in BRAF kinase domain (V600E) is most commonly observed. It leads to constitutive activation of the BRAF kinase and the downstream mitogen-activated protein kinase (MAPK) pathway, which is a key mediator of tumor proliferation. The *BRAF* V600E mutation is more frequently seen in female or older patients or in patients with high-level microsatellite instability (MSI-H) and those with right-sided tumor or mucinous histology.^[@bibr4-1758835918820298]^ It is well-known that *BRAF* V600E mutant colorectal cancer is less likely to respond to standard chemotherapy and is associated with short survival.^[@bibr1-1758835918820298],[@bibr5-1758835918820298][@bibr6-1758835918820298]--[@bibr7-1758835918820298]^ In a pooled analysis of four trials evaluating first-line chemotherapy, overall survival (OS) was extremely poor in patients with *BRAF* V600E mutation \[hazard ratio (HR) = 1.91, 95% confidence interval (CI) = 1.66--2.19, median OS = 11.4 *versus* 17.2 months).^[@bibr1-1758835918820298]^

Several approaches have been attempted to improve the treatment outcomes for mCRC patients with *BRAF* V600E mutation. Loupakis *et al*. prospectively evaluated FOLFOXIRI (5-FU/leucovorin+oxaliplatin+irinotecan) plus bevacizumab and reported encouraging outcomes in the *BRAF* V600E mutant population (median OS = 24.1 months).^[@bibr8-1758835918820298]^ In addition, the TRIBE phase III trial showed that patients with *BRAF* mutations gained greater benefits from FOLFOXIRI plus bevacizumab than from FOLFIRI plus bevacizumab (HR = 0.54, 95% CI = 0.24--1.20).^[@bibr9-1758835918820298]^ Consequently, FOLFOXIRI plus bevacizumab is considered to be an option for first-line therapy and is recommended by the European Society of Medical Oncology (ESMO) guidelines as the preferred choice of regimen.^[@bibr10-1758835918820298]^

Following the successful development of targeted therapies against malignant melanoma, targeted therapies for *BRAF* mutation have also been studied in the context of mCRC. BRAF inhibitor monotherapy is less effective for colorectal cancer compared with melanoma.^[@bibr11-1758835918820298],[@bibr12-1758835918820298]^ Dual or triple regimens in combination with BRAF inhibitors and anti-epidermal growth factor receptor (EGFR) have been under development exclusively in the setting of second- or later lines of chemotherapy. Early results have shown more favorable antitumor response compared with that of BRAF inhibitor monotherapy. Currently, a randomized, phase III study to evaluate encorafenib, a BRAF inhibitor plus cetuximab with or without binimetinib, and a MEK inhibitor *versus* investigator's choice regimens is ongoing for *BRAF* V600E mutant mCRC in second- or third- line settings (ClinicalTrials.gov identifier: NCT02928224).

In clinical trials, prognostic factors play an essential role. Randomized trials require stratification factors that have a prognostic impact on survival. Furthermore, identification of patients who are at an increased risk of early mortality is also important to ensure chemotherapy-related safety. However, there have been no reports that exclusively included only *BRAF* mutant mCRC patients in the exploration of prognostic factors. Prognostic factors applicable to the overall mCRC patient population may not be valid for *BRAF* mutant patients since *BRAF* mutation itself is a powerful prognostic factor. In the midst of drug development through clinical trials, identification of prognostic factors among *BRAF* mutant mCRC can be useful for patient stratification and for the exclusion of patients who are unfit for clinical trials. In addition, there are only a few reports focused on second- or later-line chemotherapy for colorectal cancer with *BRAF* V600E mutation and there is a lack of reference data pertaining to treatment outcomes.^[@bibr13-1758835918820298],[@bibr14-1758835918820298]^ Therefore, we retrospectively examined the effectiveness of second-line chemotherapy and evaluated prognostic factors for patients with *BRAF* V600E mutant mCRC.

Patients and methods {#section6-1758835918820298}
====================

Identification of patients {#section7-1758835918820298}
--------------------------

This was a retrospective study of mCRC patients with *BRAF* mutation who received second-line chemotherapy. We reviewed a computerized database of patients with colorectal cancer who had unresectable metastatic lesions and who received chemotherapy at the Aichi Cancer Center Hospital between January 2007 and March 2017. Patients with confirmed *BRAF* V600E mutation were included in the analysis. Among these patients, we identified the patients who underwent second-line chemotherapy. This study was approved by the Institutional Review Board at the Aichi Cancer Center Hospital (No. 2015-1-049). Written informed consent for clinical treatment and this study was obtained from all patients.

Molecular testing {#section8-1758835918820298}
-----------------

DNA extracted from surgical or tumor biopsy specimens were amplified by polymerase chain reaction (PCR) assays. From 2007 to 2014, the cycleave PCR methods were applied using core kits (TAKARA, Co., Japan) to detect *KRAS* and *BRAF* V600E mutations.^[@bibr15-1758835918820298]^ Since 2014, reverse sequence-specific oligonucleotide with PCR (PCR-rSSO) has been applied using multiplex kits, GENOSEARCH MuPACK (MBL, Japan) to detect *KRAS/NRAS* and *BRAF* V600E mutation, or GENOSEARCH BRAF (MBL, Japan) to detect *BRAF* mutations including non-V600E mutations.^[@bibr16-1758835918820298]^ Microsatellite instability (MSI) status was determined by PCR from cancerous and normal tissues or by immunohistochemistry for mismatch repair proteins.

Statistical analyses {#section9-1758835918820298}
--------------------

Patient characteristics were determined at the initiation of second-line chemotherapy. Adjuvant therapies were not counted as treatment lines and first-line chemotherapy was defined as the first systemic treatment administered in the metastatic setting. We defined right-sided colon cancer as that of the cecum and the ascending colon up to the splenic flexure. The Glasgow Prognostic Score (GPS) was calculated as follows: the presence of both elevated CRP level (\>1.0 mg/dL) and hypoalbuminemia (\<3.5 g/dL) was awarded a score of 2, the presence of only one of these abnormalities was awarded a score of 1, and the presence of neither of these was scored as 0.^[@bibr17-1758835918820298]^

Survival was calculated using the Kaplan--Meier method. The median follow-up period was calculated from the follow up among the individuals with censored cases. Progression-free survival (PFS) was defined as the time between the initiation of second-line chemotherapy and radiographic progression or death from any cause. OS was defined as the time between the initiation of second-line chemotherapy and death from any cause. Tumor response was assessed by RECIST version 1.1 if patients had measurable lesions.

Univariate and multivariate analyses were performed using Cox proportional hazards models. Factors associated with *p* values \<0.1 in univariate analysis were included in multivariate analyses and a forward stepwise method selection procedure was used. All tests were two-sided, and *p* \< 0.05 was considered statistically significant.

Results {#section10-1758835918820298}
=======

Patient characteristics {#section11-1758835918820298}
-----------------------

Of 80 *BRAF* mutant mCRC patients, four patients harbored *BRAF* non-V600E mutation, three patients received best supportive care (BSC) alone, and 73 patients with *BRAF* V600E mutation received systemic chemotherapy. Of the 64 patients who experienced failure of first-line chemotherapy, BSC alone was provided for 12 patients. Accordingly, a total of 52 patients met our inclusion criteria ([Figure 1](#fig1-1758835918820298){ref-type="fig"}). The baseline patient characteristics are listed in [Table 1](#table1-1758835918820298){ref-type="table"}. The median age was 59 years (range: 28--86). Consistent with previous studies, more than half of the patients were female (60%) and had right-sided primary (58%) and peritoneal metastases (69%). The proportion of patients with histologically poorly differentiated, signet ring cells or mucinous components was relatively high (37%). Seven patients (13%) had an Eastern Cooperative Oncology Group performance status (ECOG PS) ⩾2. An total of 24 (48%), 13 (26%), and 13 (26%) patients had GPS of 0, 1, and 2, respectively. The GPS could not be evaluated for two patients owing to missing data. Although most patients had undergone doublet regimens with or without biologics agents as first-line chemotherapy, five (10%) patients had received FOLFOXIRI regimen. One patient received a triple-combination regimen that included a BRAF inhibitor and one patient had received anti-PD-1 antibody. Quite a few patients (46%) developed early progression (first-line chemotherapy PFS [≤]{.ul}6 months). *KRAS* status was routinely evaluated along with *BRAF* status, and all patients had the *KRAS* wild type. MSI status was evaluated for 12 patients. In 2 out of these 12 patients, MSI-H was determined.

![Study flow chart.](10.1177_1758835918820298-fig1){#fig1-1758835918820298}

###### 

Patient characteristics.

![](10.1177_1758835918820298-table1)

                                                                              **Patients (*n* = 52)**
  --------------------------------------------------------------------------- -------------------------
  Age, years                                                                  
  ** Median (range)**                                                         59 (28--86)
  Gender                                                                      
   Male                                                                       21 (40%)
   Female                                                                     31 (60%)
  ECOG PS                                                                     
   0--1                                                                       45 (87%)
   2                                                                          5 (10%)
   3                                                                          2 (4%)
  Histology                                                                   
   Well or moderately differentiated                                          33 (63%)
   Poorly differentiated (Por), Signet-cell (Sig) or Mucinous (Muc)           19 (37%)
  MSI status                                                                  
   MSI-High                                                                   2 (4%)
   Microsatellite stable                                                      10 (19%)
   Unknown                                                                    40 (77%)
  Primary tumor site                                                          
   Right-sided                                                                30 (58%)
   Left-sided                                                                 22 (42%)
  Site of metastasis^[a](#table-fn1-1758835918820298){ref-type="table-fn"}^   
   Liver                                                                      30 (58%)
   Lung                                                                       19 (37%)
   Peritoneum                                                                 36 (69%)
   Lymph node                                                                 28 (54%)
  Number of metastasis                                                        
  ** 1**                                                                      10 (19%)
   ⩾2                                                                         41 (81%)
  Resection of primary tumor                                                  
   Yes                                                                        37 (71%)
   No                                                                         15 (29%)
  Adjuvant therapy                                                            
   Yes                                                                        15 (29%)
   No                                                                         37 (71%)
  WBC (/mm^2^ **)**                                                           
   \<10,000                                                                   43 (83%)
   ⩾10,000                                                                    9 (17%)
  LDH (IU/L)                                                                  
   \<240                                                                      28 (54%)
   ⩾240                                                                       24 (46%)
  ALP (IU/L)                                                                  
   \<300                                                                      17 (33%)
   ⩾300                                                                       35 (67%)
  Glasgow Prognostic Score                                                    
   0                                                                          24 (48%)
   1                                                                          13 (26%)
   2                                                                          13 (26%)
   Unknown                                                                    2 (4%)
  First-line chemotherapy                                                     
   Doublet with or without biologics                                          43 (83%)
   FOLFOXIRI with or without biologics                                        15 (10%)
   Others                                                                     4 (8%)
  PFS in first-line chemotherapy                                              
   \<6 months                                                                 24 (46%)
   ⩾6 months                                                                  28 (54%)

^a^There is some overlap.

ALP, alkaline phosphatase; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOXIRI, 5-FU/leucovorin+oxaliplatin+irinotecan; LDH, lactate dehydrogenase; MSI, microsatellite instability; PFS, progression-free survival; WBC, white blood cells.

Regimes used as second-line chemotherapy are listed in [Table 2](#table2-1758835918820298){ref-type="table"}. Treatment regimens were classified into three strategies. A total of 28 (54%) patients received cytotoxic doublet or triplet regimens with conventional approved biologics. Four (8%) patients were treated with study drugs including BRAF inhibitors. The remaining 20 (38%) patients were treated with other regimens. No interaction was observed between treatment strategies and the prognostic factors described below. A total of 40 (77%) patients received oxaliplatin- or irinotecan-based regimens. Fifteen (29%) patients received adjuvant therapy and six (12%) developed recurrence either during adjuvant therapy or within 6 months after the last administration.

###### 

Regimens for second-line chemotherapy.

![](10.1177_1758835918820298-table2)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Regimens       Cytotoxic doublet or triplet with conventional approved biologics (*n* = 28)   Other regimens (*n* = 20)   Study drugs including BRAF inhibitors ( *n* = 4)   *p* value
  -------------- ------------------------------------------------------------------------------ --------------------------- -------------------------------------------------- -----------
  **ECOG PS**\   26/2                                                                           15/5                        4/0                                                0.17
  0-1/2                                                                                                                                                                        

  **LDH**\       16/12                                                                          9/11                        3/1                                                0.58
  \<240/⩾240                                                                                                                                                                   

  **GPS**\       15/7/5                                                                         7/4/8                       2/2/0                                              0.27
  0/1/2                                                                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Anti-EGFR, anti-epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, 5-FU/leucovorin; FOLFOXIRI, 5-FU/leucovorin+oxaliplatin+irinotecan; GPS, Glasgow Prognostic Score; LDH, lactate dehydrogenase.

Treatment results {#section12-1758835918820298}
-----------------

The median PFS and OS were 2.5 (95% CI = 1.91--4.11) and 6.5 (95% CI = 4.30--9.63) months, respectively, with a median follow-up period of 11.3 months ([Figure 2](#fig2-1758835918820298){ref-type="fig"}). The 1-year survival rate was 30.1 (95% CI = 17.0--41.6)%. For patients treated with the most frequently used therapy, doublet regimens plus bevacizumab, the median PFS and OS were 4.3 (95% CI = 1.94--5.88) and 8.8 (95% CI = 5.39--13.37) months, respectively. Among the 44 patients who had measurable lesions, the overall response and disease control rates were 7% and 48%, respectively ([Figure 3](#fig3-1758835918820298){ref-type="fig"}). All regimens that elicited a partial response were comprised of BRAF inhibitors in combination with anti-EGFR anti bodies, which provided response rates of 75% (three of four) and disease control rates of 100%. Therefore, the overall response and disease control rates were 0 and 43%, after exclusion of four patients who were treated with study drugs in clinical trials.

![Survival curve for overall patients: (A) progression-free survival; and (B) overall survival.](10.1177_1758835918820298-fig2){#fig2-1758835918820298}

![Change in tumor size. Waterfall plot showing the best percentage change from baseline in tumor measurement using RECIST version 1.1.\
\*Patients who were treated with study drugs in clinical trials.](10.1177_1758835918820298-fig3){#fig3-1758835918820298}

Prognostic factors {#section13-1758835918820298}
------------------

Results of univariate and multivariate analysis for OS are presented in [Table 3](#table3-1758835918820298){ref-type="table"}. On univariate analysis, four factors showed a significant association with survival: the GPS, high white blood cell (WBC) count, elevated lactate dehydrogenase (LDH), and ECOG-PS. Multivariate analysis revealed that the GPS, elevated LDH, and ECOG-PS were independent prognostic factors for OS. Meanwhile, the well-known negative prognostic factors such as right-sided tumor location were not prognostic. The median PFSs in patients with GPS of 0, 1, and 2 were 4.7, 1.7, and 0.9 months, respectively. The median OSs in patients with GPS of 0, 1, and 2 were 10.0, 5.0, and 1.3 months, respectively ([Figure 4](#fig4-1758835918820298){ref-type="fig"}). After exclusion of patients with ECOG-PS ⩾2, univariate analysis for OS showed that prognostic value of GPS was still maintained (GPS = 1, HR = 2.24, 95% CI = 1.02--4.90 and GPS = 2, HR = 10.27, 95% CI = 3.49--30.2).

###### 

Univariate and multivariate analyses for OS.

![](10.1177_1758835918820298-table3)

  ----------------------------------------------------------------------------------------
  Factors                           Univariate\     *p*    Multivariate\   *p*    
                                    HR                     HR                     
  --------------------------------- --------------- ------ --------------- ------ --------
  Age                               ⩾60             0.78   0.42                   

  Gender                            Female          0.89   0.70                   

  ECOG-PS                           ⩾2              24.1   \<0.01          7.41   \<0.01

  Histology                         Por, Sig, Muc   1.18   0.60                   

  Primary tumor location            Right-sided     0.80   0.46                   

  Peritoneal metastasis             Present         0.94   0.84                   

  Number of metastasis              ⩾2              1.29   0.55                   

  Colostomy                         No              1.71   0.09                   

  WBC                               ⩾10,000         2.23   0.03                   

  LDH                               ⩾240            2.56   \<0.01          2.61   \<0.01

  ALP                               ⩾300            1.43   0.27                   

  GPS (*versus* 0)                  1               2.21   0.05            2.42   0.03

                                    2               15.3   \<0.01          8.82   \<0.01

  First-line chemotherapy regimen   Triplet         2.30   0.08                   

  PFS in first-line chemotherapy    \<6 months      1.84   0.05                   
  ----------------------------------------------------------------------------------------

ALP, alkaline phosphatase; ECOG PS, Eastern Cooperative Oncology Group performance status; GPS, Glasgow Prognostic Score; HR, hazard ratio; LDH, lactate dehydrogenase; Muc, Mucinous; Por, poorly differentiated; PFS, progression-free survival; Sig, signet cell; WBC, white blood cells.

![Survival curve according to Glasgow Prognostic Score (GPS): (A) progression-free survival according to GPS; (B) overall survival according to GPS.](10.1177_1758835918820298-fig4){#fig4-1758835918820298}

Subsequent therapies {#section14-1758835918820298}
--------------------

Among the 50 patients who discontinued their second-line chemotherapy, most patients stopped the treatment due to disease progression (87%). Among the fifty patients, twenty-five (50%) received third-line chemotherapy and the remaining (50%) received BSC alone. The third-line chemotherapy regimens were as follows: fluoropyrimidine-based regimens (seven patients), trifluridine/tipiracil (6), anti-EGFR antibodies plus irinotecan (5), anti-EGFR antibody monotherapy (4), regorafenib (2), and pilot studies of antimicrotubule agents (1).

Discussion {#section15-1758835918820298}
==========

In this study, we identified GPS at the initiation of second-line treatment as a meaningful prognostic factor in mCRC patients with *BRAF* V600E mutation. To the best of our knowledge, this is the first study to explore significant prognostic factors and demonstrate the usefulness of the GPS for *BRAF* mutant mCRC. It is noteworthy that survival curves according to the GPS separated clearly. Patients with a GPS of 2 had a median PFS of 0.9 months and a median OS of 1.3 months, which indicates that these patients are unfit for enrolment in clinical trials. GPS is also useful in that the score (0 *versus* 1) serves as a stratification factor. Thus, GPS seems to be an especially efficient factor for use in clinical trials. GPS, an inflammation-based score, has been shown to be a prognostic indicator in various types of cancers.^[@bibr18-1758835918820298][@bibr19-1758835918820298][@bibr20-1758835918820298][@bibr21-1758835918820298]--[@bibr22-1758835918820298]^ For colorectal cancer, GPS has been found to be a useful independent predictor of tumor stage.^[@bibr23-1758835918820298][@bibr24-1758835918820298]--[@bibr25-1758835918820298]^ Although the modified GPS (mGPS), in which hypoalbuminemia alone is classified as mGPS of 0, was proposed later,^[@bibr26-1758835918820298]^ it remains unclear whether GPS or mGPS is a more valuable marker. In our analysis, the survival curves separated more clearly according to GPS than mGPS (data not shown).

In our study, the 52 patients who underwent second-line chemotherapy had a dismal prognosis; the median PFS and OS were 2.5 (95% CI = 1.91--4.11) and 6.5 (95% CI = 4.30--9.63) months, respectively. Moreover, the overall response was 0% after exclusion of the four patients who were treated with study drugs in clinical trials. Several clinical trials in the second-line setting performed subgroup analyses of *BRAF* mutant patients and the reported median PFS and OS were 1.8--3.5 and 4.4--6.7 months,^[@bibr14-1758835918820298]^ respectively, which is in line with our results. Morris *et al*. retrospectively analyzed metastatic colorectal cancer with *BRAF* mutation and reported that the median PFS in patients who received second-line therapy was 2.5 months.^[@bibr13-1758835918820298]^ Seligmann *et al*. assessed three randomized trials and compared survival outcomes between *BRAF* mutant and wild-type patients.^[@bibr27-1758835918820298]^ In that study, *BRAF* mutation conferred a markedly worse survival after first-line therapy, while there was no difference in first-line PFS and disease control rate. The authors proposed that patients with *BRAF* mutation were likely to develop rapid tumor growth after chemotherapy failure. It is evident that there is an urgent need to explore a breakthrough approach in second- or later-line chemotherapy for *BRAF* V600E-mutated mCRC patients.

Selective BRAF inhibition by small molecules has been considered to be a promising strategy. Preclinical studies have demonstrated that BRAF inhibition, in addition to the blockage of other signal pathways, is necessary to prohibit tumor growth.^[@bibr28-1758835918820298],[@bibr29-1758835918820298]^ Based on these findings, dual or triple regimens with BRAF inhibitors in combination with EGFR antibodies, MEK inhibitors, or PI3K inhibitors have been tested. Dabrafenib (BRAF inhibitor) plus panitumumab plus trametinib (MEK inhibitor) yielded an overall response rate of 18% and a disease control rate of 67%.^[@bibr30-1758835918820298]^ Phase II trials comparing encorafenib (BRAF inhibitor) plus cetuximab and encorafenib plus cetuximab plus alpelisib (PI3K inhibitor) showed an overall response rate of 22% and 27%, respectively. The median PFSs were 4.2 and 5.4 months for the doublet and triplet regimen (HR = 0.69, 95% CI = 0.43--1.11), respectively.^[@bibr31-1758835918820298]^ The SWOG S1406 trial, a randomized phase II trial of irinotecan and cetuximab with or without vemurafenib, showed that PFS was extended with the addition of vemurafenib (HR = 0.42, 95% CI = 0.26--0.66) with a median PFS of 4.4 *versus* 2.0 months. The objective response rate was also higher in the irinotecan and cetuximab with vemurafenib group (16% *versus* 4%).^[@bibr32-1758835918820298]^ Compared with BRAF inhibitor monotherapy, these results were encouraging. Indeed, only the patients who received study drugs including BRAF inhibitors achieved a partial response in our study, which indicates that regimens which include BRAF inhibitors and EGFR antibodies are promising.

Of interest, well-known negative prognostic factors such as histological type or primary tumor location were associated with *BRAF* mutation, but were not prognostically relevant when the analysis was limited to patients with *BRAF* mutation. Lee *et al*. demonstrated that right-sided tumor was associated with worse prognosis but was not an independent prognostic factor when adjusted for other variables including *BRAF* mutation status, which seems to be consistent with our results.^[@bibr33-1758835918820298]^ It may be because *BRAF* mutation is a powerful prognostic factor. From our findings, we believe that it is essential to identify independent prognostic factors among *BRAF* mutant patients. In a recent study, patients with colorectal cancer with *BRAF* mutation were divided into two groups (BM1 and BM2) using clustering based on genetic profile analysis.^[@bibr34-1758835918820298]^ It is suggested that the two subgroups were dependent on different signal pathways, and that the differences affected the sensitivity to chemotherapeutic agents and the prognosis of the two subgroups differed significantly. These results reinforce the presence of heterogeneity among *BRAF* mutations, which is in line with our findings that the survival outcomes differed according to baseline patient characteristics such as GPS.

There are a few limitations to our study. First, this is a retrospective analysis from a single institution and included a small sample size. Prognostic factors identified in our study should be validated in further research. Biomarker analysis is also important to reveal the biological background behind our findings. Second, our study enrolled various patients including patients with poor condition who are usually ineligible for participation in clinical trials. However, the prognostic value of GPS was intact even after exclusion of patients with ECOG-PS ⩾2. Third, the treatment regimens differed considerably because the standard second-line chemotherapy for metastatic colorectal cancer with *BRAF* V600E mutation remains unclear. In the currently ongoing phase III trial (ClinicalTrials.gov identifier: NCT02928224), investigator's choice regimens (FOLFIRI plus cetuximab or irinotecan plus cetuximab) are adopted as the control arm. Moreover, our study was a prognostic, not a predictive, analysis. All the regimens used in our study have been shown to be effective for metastatic colorectal cancer in previous studies and therefore can be included in the analysis. Fourth, MSI status was evaluated for only a few patients (12 of 52, 23%) since routine MSI examination is not covered by Japanese national insurance. The frequency of colorectal cancer with deficient mismatch repair (MMR) is lower in Japan and other Asian countries compared with that in Western countries.^[@bibr35-1758835918820298][@bibr36-1758835918820298]--[@bibr37-1758835918820298]^ In a study by Fujiyoshi *et al*., MSI-H tumor was detected in 3.7% of Japanese mCRC patients and the frequency in *BRAF* mutant patients was 16.0%.^[@bibr37-1758835918820298]^ However, it was reported that no significant survival differences were observed irrespective of MSI status.^[@bibr1-1758835918820298]^ MSI has shown to be an effective biomarker for immune check inhibitors^[@bibr38-1758835918820298],[@bibr39-1758835918820298]^ and the screening system is rapidly spreading in Japan. Despite these limitations, our study is the first to report the detailed outcomes of second-line chemotherapy and identify prognostic factors for *BRAF* mutant mCRC.

In summary, the results of second-line chemotherapy for mCRC with *BRAF* V600E mutation were extremely poor. Clinical trials of new agents and further development of treatment strategies are urgently required. GPS, elevated LDH and ECOG-PS were shown to be independent prognostic factors for OS. In particular, it is suggested that GPS is useful in future clinical trials to serve as a stratification factor (GPS 0 *versus* 1) and to identify patients who are unfit for trials (GPS 2).
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